Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Pressure is growing for greater disclosure of study results, which may shift industry R&D, Schering compliance VP Saunders says. Former DoJ attorney Bentivoglio suggests that disclosure requirements would include cost-effectiveness data.
You may also be interested in...
HHS Should Track All Rx Clinical Trials, AMA Says
All trials should be registered to ensure results are publicly available, physicians’ association says. Institutional review boards should not approve trials unless they are registered, AMA policy urges.
HHS Should Track All Rx Clinical Trials, AMA Says
All trials should be registered to ensure results are publicly available, physicians’ association says. Institutional review boards should not approve trials unless they are registered, AMA policy urges.
FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators
Finance Committee staff continues its inquiry into how FDA handled information on a possible link between antidepressants and suicidality. A June 2 letter asks for contact information of former Office of Drug Safety employees and a list of meetings between CDER officials and manufacturers.